Diabetes mellitus in transfemoral transcatheter aortic valve implantation: a propensity matched analysis.
Aortic valve stenosis
Bleeding
Diabetes mellitus
Insulin
Mortality
Stroke
TAVI
Transcatheter aortic valve replacement
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 11 2022
16 11 2022
Historique:
received:
27
01
2022
accepted:
18
09
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Diabetes Mellitus (DM) affects a third of patients with symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). DM is a well-known risk factor for cardiac surgery, but its prognostic impact in TAVI patients remains controversial. This study aimed to evaluate outcomes in diabetic patients undergoing TAVI. This multicentre registry includes data of > 12,000 patients undergoing transfemoral TAVI. We assessed baseline patient characteristics and clinical outcomes in patients with DM and without DM. Clinical outcomes were defined by the second valve academic research consortium. Propensity score matching was applied to minimize potential confounding. Of the 11,440 patients included, 31% (n = 3550) had DM and 69% (n = 7890) did not have DM. Diabetic patients were younger but had an overall worse cardiovascular risk profile than non-diabetic patients. All-cause mortality rates were comparable at 30 days (4.5% vs. 4.9%, RR 0.9, 95%CI 0.8-1.1, p = 0.43) and at one year (17.5% vs. 17.4%, RR 1.0, 95%CI 0.9-1.1, p = 0.86) in the unmatched population. Propensity score matching obtained 3281 patient-pairs. Also in the matched population, mortality rates were comparable at 30 days (4.7% vs. 4.3%, RR 1.1, 95%CI 0.9-1.4, p = 0.38) and one year (17.3% vs. 16.2%, RR 1.1, 95%CI 0.9-1.2, p = 0.37). Other clinical outcomes including stroke, major bleeding, myocardial infarction and permanent pacemaker implantation, were comparable between patients with DM and without DM. Insulin treated diabetics (n = 314) showed a trend to higher mortality compared with non-insulin treated diabetics (n = 701, Hazard Ratio 1.5, 95%CI 0.9-2.3, p = 0.08). EuroSCORE II was the most accurate risk score and underestimated 30-day mortality with an observed-expected ratio of 1.15 in DM patients, STS-PROM overestimated actual mortality with a ratio of 0.77 and Logistic EuroSCORE with 0.35. DM was not associated with mortality during the first year after TAVI. DM patients undergoing TAVI had low rates of mortality and other adverse clinical outcomes, comparable to non-DM TAVI patients. Our results underscore the safety of TAVI treatment in DM patients. The study is registered at clinicaltrials.gov (NCT03588247).
Sections du résumé
BACKGROUND
Diabetes Mellitus (DM) affects a third of patients with symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). DM is a well-known risk factor for cardiac surgery, but its prognostic impact in TAVI patients remains controversial. This study aimed to evaluate outcomes in diabetic patients undergoing TAVI.
METHODS
This multicentre registry includes data of > 12,000 patients undergoing transfemoral TAVI. We assessed baseline patient characteristics and clinical outcomes in patients with DM and without DM. Clinical outcomes were defined by the second valve academic research consortium. Propensity score matching was applied to minimize potential confounding.
RESULTS
Of the 11,440 patients included, 31% (n = 3550) had DM and 69% (n = 7890) did not have DM. Diabetic patients were younger but had an overall worse cardiovascular risk profile than non-diabetic patients. All-cause mortality rates were comparable at 30 days (4.5% vs. 4.9%, RR 0.9, 95%CI 0.8-1.1, p = 0.43) and at one year (17.5% vs. 17.4%, RR 1.0, 95%CI 0.9-1.1, p = 0.86) in the unmatched population. Propensity score matching obtained 3281 patient-pairs. Also in the matched population, mortality rates were comparable at 30 days (4.7% vs. 4.3%, RR 1.1, 95%CI 0.9-1.4, p = 0.38) and one year (17.3% vs. 16.2%, RR 1.1, 95%CI 0.9-1.2, p = 0.37). Other clinical outcomes including stroke, major bleeding, myocardial infarction and permanent pacemaker implantation, were comparable between patients with DM and without DM. Insulin treated diabetics (n = 314) showed a trend to higher mortality compared with non-insulin treated diabetics (n = 701, Hazard Ratio 1.5, 95%CI 0.9-2.3, p = 0.08). EuroSCORE II was the most accurate risk score and underestimated 30-day mortality with an observed-expected ratio of 1.15 in DM patients, STS-PROM overestimated actual mortality with a ratio of 0.77 and Logistic EuroSCORE with 0.35.
CONCLUSION
DM was not associated with mortality during the first year after TAVI. DM patients undergoing TAVI had low rates of mortality and other adverse clinical outcomes, comparable to non-DM TAVI patients. Our results underscore the safety of TAVI treatment in DM patients.
TRIAL REGISTRATION
The study is registered at clinicaltrials.gov (NCT03588247).
Identifiants
pubmed: 36384656
doi: 10.1186/s12933-022-01654-x
pii: 10.1186/s12933-022-01654-x
pmc: PMC9670618
doi:
Banques de données
ClinicalTrials.gov
['NCT03588247']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Informations de copyright
© 2022. The Author(s).
Références
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
Catheter Cardiovasc Interv. 2021 Dec 1;98(7):E1058-E1065
pubmed: 34611993
Int J Cardiol. 2021 Jan 1;322:65-69
pubmed: 32814108
Ann Thorac Surg. 2018 Apr;105(4):1137-1143
pubmed: 29394992
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
EuroIntervention. 2012 Nov 22;8(7):782-95
pubmed: 23022744
Ann Thorac Surg. 2010 Jul;90(1):124-30
pubmed: 20609762
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Circ Cardiovasc Interv. 2017 Nov;10(11):
pubmed: 29138245
JAMA. 2007 Nov 28;298(20):2367-8; author reply 2368
pubmed: 18042912
Eur Heart J. 2019 Feb 1;40(5):456-465
pubmed: 30590565
Diabetologia. 2021 Nov;64(11):2562-2574
pubmed: 34494136
Am J Cardiol. 2015 Dec 15;116(12):1898-903
pubmed: 26602074
Int J Cardiol. 2019 Dec 15;297:22-29
pubmed: 31630816
Cardiovasc Diabetol. 2019 Mar 11;18(1):27
pubmed: 30857532
Eur J Cardiothorac Surg. 1999 Jul;16(1):9-13
pubmed: 10456395
Cardiovasc Diabetol. 2018 Oct 16;17(1):135
pubmed: 30326902
J Am Coll Cardiol. 2014 Mar 25;63(11):1090-9
pubmed: 24291272
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Cardiovasc Diabetol. 2017 Nov 09;16(1):144
pubmed: 29121921
EuroIntervention. 2018 Jan 20;13(13):1520-1526
pubmed: 28994653
Cardiovasc Diabetol. 2019 May 28;18(1):63
pubmed: 31138207
J Am Coll Cardiol. 2000 Mar 1;35(3):563-8
pubmed: 10716456
Circulation. 2006 May 2;113(17):2113-9
pubmed: 16636166
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967